Related references
Note: Only part of the references are listed.Effect of mTORC1/mTORC2 inhibition on T cell function: potential role in graft-versus-host disease control
Ma Carmen Herrero-Sanchez et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Profound blockade of T cell activation requires concomitant inhibition of different class I PI3K isoforms
Belen Blanco et al.
IMMUNOLOGIC RESEARCH (2015)
Comparative effect of two pan-class I PI3K inhibitors used as anticancer drugs on human T cell function
Belen Blanco et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2015)
Cotargeting the PI3K and RAS Pathways for the Treatment of Neuroendocrine Tumors
Joseph D. Valentino et al.
CLINICAL CANCER RESEARCH (2014)
Combinatorial action of transcription factors orchestrates cell cycle-dependent expression of the ribosomal protein genes and ribosome biogenesis
Nagisa Nosrati et al.
FEBS JOURNAL (2014)
ZSTK474, a novel PI3K inhibitor, modulates human CD14+ monocyte-derived dendritic cell functions and suppresses experimental autoimmune encephalomyelitis
Zhenyi Xue et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2014)
Activation of AR Sensitizes Breast Carcinomas to NVP-BEZ235's Therapeutic Effect Mediated by PTEN and KLLN Upregulation
Yu Wang et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Effect of Inhibiting the Signal of Mammalian Target of Rapamycin on Memory T Cells
S. Chen et al.
TRANSPLANTATION PROCEEDINGS (2014)
Efficacy of dual PI-3K and mTOR inhibitors in Vitro and in Vivo in acute lymphoblastic leukemia
Jacky Wong et al.
ONCOTARGET (2014)
PI3K Inhibition Augments the Efficacy of Rapamycin in Suppressing Proliferation of Epstein-Barr Virus (EBV) plus B Cell Lymphomas
S. Furukawa et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2013)
Defining the Role of Sirolimus in the Management of Graft-versus-Host Disease: From Prophylaxis to Treatment
Ahmed Abouelnasr et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Understanding, recognizing, and managing toxicities of targeted anticancer therapies
Grace K. Dy et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2013)
Selective Inhibition of Phosphoinositide 3-Kinase p110α Preserves Lymphocyte Function
Lomon So et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Stimulatory effect of insulin on theca-interstitial cell proliferation and cell cycle regulatory proteins through MTORC1 dependent pathway
Murugesan Palaniappan et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2013)
Differential Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR Pathway in Acute Lymphoblastic Leukemia
Susanne Badura et al.
PLOS ONE (2013)
Novel treatment concepts for graft-versus-host disease
Dominik Wolf et al.
BLOOD (2012)
Immunotherapy with PI3K Inhibitor and Toll- Like Receptor Agonist Induces IFN-γ+IL-17+ Polyfunctional T Cells That Mediate Rejection of Murine Tumors
Neil A. Marshall et al.
CANCER RESEARCH (2012)
Transcription Factor Foxo1 Represses T-bet-Mediated Effector Functions and Promotes Memory CD8+ T Cell Differentiation
Rajesh R. Rao et al.
IMMUNITY (2012)
Androgen Receptor Enhances p27 Degradation in Prostate Cancer Cells through Rapid and Selective TORC2 Activation
Zi Fang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Mammalian Target of Rapamycin Integrates Diverse Inputs To Guide the Outcome of Antigen Recognition in T Cells
Adam T. Waickman et al.
JOURNAL OF IMMUNOLOGY (2012)
Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone
Yuhuan Zheng et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2012)
Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
Sauveur-Michel Maira et al.
MOLECULAR CANCER THERAPEUTICS (2012)
A repertoire-independent and cell-intrinsic defect in murine GVHD induction by effector memory T cells
Kathryn W. Juchem et al.
BLOOD (2011)
Rapamycin-sensitive signals control TCR/CD28-driven Ifng, Il4 and Foxp3 transcription and promoter region methylation
Romana Tomasoni et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2011)
PI3Kγ controls leukocyte recruitment, tissue injury, and lethality in a model of graft-versus-host disease in mice
Marina G. M. Castor et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2011)
The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2
Greg M. Delgoffe et al.
NATURE IMMUNOLOGY (2011)
Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer
Matthew T. Burger et al.
ACS MEDICINAL CHEMISTRY LETTERS (2011)
Effects of 4E-BP1 expression on hypoxic cell cycle inhibition and tumor cell proliferation and survival
Bryan C. Barnhart et al.
CANCER BIOLOGY & THERAPY (2010)
Activity of the Novel Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 against T-Cell Acute Lymphoblastic Leukemia
Francesca Chiarini et al.
CANCER RESEARCH (2010)
Mammalian Target of Rapamycin Protein Complex 2 Regulates Differentiation of Th1 and Th2 Cell Subsets via Distinct Signaling Pathways
Keunwook Lee et al.
IMMUNITY (2010)
The role of mTOR in memory CD8+T-cell differentiation
Koichi Araki et al.
IMMUNOLOGICAL REVIEWS (2010)
Early events governing memory CD8+ T-cell differentiation
Joshua J. Obar et al.
INTERNATIONAL IMMUNOLOGY (2010)
mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs
Ryan J. O. Dowling et al.
SCIENCE (2010)
Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235
Douglas W. McMillin et al.
CANCER RESEARCH (2009)
The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma
Philipp Baumann et al.
EXPERIMENTAL CELL RESEARCH (2009)
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
Sauveur-Michel Maira et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: Analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease
Jo-Anne H. van Burik et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis
Francisco M. Marty et al.
BLOOD (2007)
AKT/PKB signaling: Navigating downstream
Brendan D. Manning et al.
CELL (2007)
A role for mammalian target of rapamycin in regulating T cell activation versus anergy
Yan Zheng et al.
JOURNAL OF IMMUNOLOGY (2007)
Antigen recognition induces phosphatidylserine exposure on the cell surface of human CD8+ T cells
Karin Fischer et al.
BLOOD (2006)
Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy
Unsu Jung et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2006)
Enhancement of cytokine-mediated NF-κB activation by phosphatidylinositol 3-kinase inhibitors in monocytic cells
Eun-Kyoung Choi et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2006)
TOR signaling in growth and metabolism
S Wullschleger et al.
CELL (2006)
TOR signaling in growth and metabolism
Stephan Wullschleger et al.
CELL (2006)
Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease: II. Pathology Working Group report
HM Shulman et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2006)
Host-reactive CD8+ memory stem cells in graft-versus-host disease
Y Zhang et al.
NATURE MEDICINE (2005)
IL-2 production in developing Th1 cells is regulated by heterodimerization of RelA and T-bet and requires T-bet serine residue 508
ES Hwang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
CD28 regulates the translation of Bcl-x(L) via the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway
LX Wu et al.
JOURNAL OF IMMUNOLOGY (2005)
Phenotypic classification of human CD8+ T cells reflecting their function:: inverse correlation between quantitative expression of CD27 and cytotoxic effector function
H Tomiyama et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2004)
Rapamycin-resistant proliferation of CD8+T cells correlates with p27kip1 down-regulation and bcl-xL induction, and is prevented by an inhibitor of phosphoinositide 3-kinase activity
JM Slavik et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Recent developments in the transcriptional regulation of cytolytic effector cells
LH Glimcher et al.
NATURE REVIEWS IMMUNOLOGY (2004)
Control of effector CD8+ T cell function by the transcription factor Eomesodermin
EL Pearce et al.
SCIENCE (2003)
ERK and p38 inhibit the expression of 4E-BP1 repressor of translation through induction of Egr-1
M Rolli-Derkinderen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Lack of specificity in skin biopsy specimens to assess for acute graft-versus-host disease in initial 3 weeks after bone-marrow transplantation
TD Kuykendall et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2003)
CD28 costimulation mediates down-regulation of p27kip1 and cell cycle progression by activation of the PI3K/PKB signaling pathway in primary human T cells
LJ Appleman et al.
JOURNAL OF IMMUNOLOGY (2002)
Share Paper
